Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer ; 129(5): 764-770, 2023 03 01.
Article in English | MEDLINE | ID: mdl-36504293

ABSTRACT

BACKGROUND: Hippocampal avoidance (HA) has been shown to preserve cognitive function in adult patients with cancer treated with whole-brain radiation therapy for brain metastases. However, the feasibility of HA in pediatric patients with brain tumors has not been explored because of concerns of increased risk of relapse in the peri-hippocampal region. Our aim was to determine patterns of recurrence and incidence of peri-hippocampal relapse in pediatric patients with medulloblastoma (MB). METHODS AND MATERIALS: We identified pediatric patients with MB treated with protons between 2002 and 2016 and who had recurrent disease. To estimate the risk of peri-hippocampal recurrence, three hippocampal zones (HZs) were delineated corresponding to ≤5 mm (HZ-1), 6 to 10 mm (HZ-2), and >10 mm (HZ-3) distance of the recurrence from the contoured hippocampi. To determine the feasibility of HA, three standard-risk patients with MB were planned using either volumetric-modulated arc therapy (VMAT) or intensity-modulated proton therapy (IMPT) plans. RESULTS: Thirty-eight patients developed a recurrence at a median of 1.6 years. Of the 25 patients who had magnetic resonance imaging of the recurrence, no patients failed within the hippocampus and only two patients failed within HZ-1. The crude incidence of peri-hippocampal failure was 8%. Both HA-VMAT and HA-IMPT plans were associated with significantly reduced mean dose to the hippocampi (p < .05). HA-VMAT and HA-IMPT plans were associated with decreased percentage of the third and lateral ventricles receiving the prescription craniospinal dose of 23.4 Gy. CONCLUSIONS: Peri-hippocampal failures are uncommon in pediatric patients with MB. Hippocampal avoidance should be evaluated in a prospective cohort of pediatric patients with MB. PLAIN LANGUAGE SUMMARY: In this study, the patterns of disease recurrence in patients with a pediatric brain tumor known as medulloblastoma treated with proton radiotherapy were examined. The majority of failures occur outside of an important structure related to memory formation called the hippocampus. Hippocampal sparing radiation plans using proton radiotherapy were generated and showed that dose to the hippocampus was able to be significantly reduced. The study provides the rationale to explore hippocampal sparing in pediatric medulloblastoma in a prospective clinical trial.


Subject(s)
Brain Neoplasms , Cerebellar Neoplasms , Medulloblastoma , Radiotherapy, Intensity-Modulated , Humans , Child , Medulloblastoma/radiotherapy , Brain Neoplasms/radiotherapy , Brain Neoplasms/secondary , Organ Sparing Treatments/methods , Organs at Risk , Protons , Prospective Studies , Radiotherapy Planning, Computer-Assisted/methods , Radiotherapy Dosage , Cranial Irradiation/adverse effects , Cranial Irradiation/methods , Neoplasm Recurrence, Local/epidemiology , Radiotherapy, Intensity-Modulated/methods , Hippocampus/diagnostic imaging , Cerebellar Neoplasms/radiotherapy
2.
J Clin Invest ; 124(5): 2113-24, 2014 May.
Article in English | MEDLINE | ID: mdl-24743147

ABSTRACT

Respiratory syncytial virus (RSV) infection accounts for approximately 64 million cases of respiratory disease and 200,000 deaths worldwide each year, yet no broadly effective prophylactic or treatment regimen is available. RSV deploys paired, self-associating, heptad repeat domains of its fusion protein, RSV-F, to form a fusogenic 6-helix bundle that enables the virus to penetrate the host cell membrane. Here, we developed hydrocarbon double-stapled RSV fusion peptides that exhibit stabilized α-helical structure and striking proteolytic resistance. Pretreatment with double-stapled RSV peptides that specifically bound to the RSV fusion bundle inhibited infection by both laboratory and clinical RSV isolates in cells and murine infection models. Intranasal delivery of a lead double-stapled RSV peptide effectively prevented viral infection of the nares. A chitosan-based nanoparticle preparation markedly enhanced pulmonary delivery, further preventing progression of RSV infection to the lung. Thus, our results provide a strategy for inhibiting RSV infection by mucosal and endotracheal delivery of double-stapled RSV fusion peptides.


Subject(s)
Nose Diseases/prevention & control , Peptides , Pneumonia, Viral/prevention & control , Respiratory Syncytial Virus Infections/prevention & control , Respiratory Syncytial Viruses , Viral Fusion Proteins , Animals , Cell Line , Chitosan/chemistry , Chitosan/pharmacology , Disease Models, Animal , Female , Mice , Mice, Inbred BALB C , Nanoparticles/chemistry , Nose Diseases/metabolism , Nose Diseases/pathology , Peptides/chemistry , Peptides/pharmacology , Pneumonia, Viral/metabolism , Pneumonia, Viral/pathology , Respiratory Syncytial Virus Infections/metabolism , Respiratory Syncytial Virus Infections/pathology , Viral Fusion Proteins/chemistry , Viral Fusion Proteins/pharmacology
3.
Proc Natl Acad Sci U S A ; 107(32): 14093-8, 2010 Aug 10.
Article in English | MEDLINE | ID: mdl-20660316

ABSTRACT

The pharmacologic utility of lengthy peptides can be hindered by loss of bioactive structure and rapid proteolysis, which limits bioavailability. For example, enfuvirtide (Fuzeon, T20, DP178), a 36-amino acid peptide that inhibits human immunodeficiency virus type 1 (HIV-1) infection by effectively targeting the viral fusion apparatus, has been relegated to a salvage treatment option mostly due to poor in vivo stability and lack of oral bioavailability. To overcome the proteolytic shortcomings of long peptides as therapeutics, we examined the biophysical, biological, and pharmacologic impact of inserting all-hydrocarbon staples into an HIV-1 fusion inhibitor. We find that peptide double-stapling confers striking protease resistance that translates into markedly improved pharmacokinetic properties, including oral absorption. We determined that the hydrocarbon staples create a proteolytic shield by combining reinforcement of overall alpha-helical structure, which slows the kinetics of proteolysis, with complete blockade of peptide cleavage at constrained sites in the immediate vicinity of the staple. Importantly, double-stapling also optimizes the antiviral activity of HIV-1 fusion peptides and the antiproteolytic feature extends to other therapeutic peptide templates, such as the diabetes drug exenatide (Byetta). Thus, hydrocarbon double-stapling may unlock the therapeutic potential of natural bioactive polypeptides by transforming them into structurally fortified agents with enhanced bioavailability.


Subject(s)
Anti-HIV Agents/chemistry , HIV Fusion Inhibitors/chemistry , Hydrocarbons/chemistry , Peptides/pharmacokinetics , Biological Availability , HIV Fusion Inhibitors/pharmacokinetics , HIV Infections/drug therapy , HIV Infections/prevention & control , Humans , Hydrocarbons/therapeutic use , Peptides/therapeutic use , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...